Issues in the incorporation of economic perspectives and evidence into Cochrane reviews
暂无分享,去创建一个
Luke Vale | Mike Drummond | David McDaid | Ian Shemilt | Kevin Marsh | Catherine Henderson | Miranda Mugford | M. Drummond | M. Mugford | K. Marsh | I. Shemilt | D. McDaid | L. Vale | Catherine Henderson | E. Bertranou | Evelina Bertranou | Jacqueline Mallander | Jacqueline Mallander
[1] G. Mowatt,et al. Systematic review of the clinical effectiveness and cost-effectiveness of oesophageal Doppler monitoring in critically ill and high-risk surgical patients. , 2009, Health technology assessment.
[2] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[3] J. Chilcott,et al. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal. , 2009, Health technology assessment.
[4] Rob W Anderson,et al. The Role of Economic Perspectives and Evidence in Systematic Review , 2010 .
[5] P. Neumann. What next for QALYs? , 2011, JAMA.
[6] John K. Roman,et al. What does cost-benefit analysis add to decision making? Evidence from the criminal justice literature , 2008 .
[7] C. Boehler. Mind the Gap! - Geographic transferability of economic evaluation in health , 2012 .
[8] Ian Shemilt,et al. Evidence- Based decisions and economics , 2013 .
[9] M. Mugford,et al. From effectiveness to efficiency: an introduction to evidence-based health economics in systematic review , 2002 .
[10] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[11] H. D. de Vet,et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria , 2005, International Journal of Technology Assessment in Health Care.
[12] Michele Tarsilla. Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.
[13] F. Sassi,et al. Equity, Efficiency and Research Synthesis , 2010 .
[14] Renee F Wilson,et al. Assessing the Impact of Economic Evidence on Policymakers in Health Care—A Systematic Review , 2012 .
[15] Gerald Gartlehner,et al. [GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence]. , 2013, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[16] M. Drummond,et al. Economics methods in Cochrane systematic reviews of health promotion and public health related interventions , 2006, BMC medical research methodology.
[17] S Bryan,et al. The use of economic evaluations in NHS decision-making: a review and empirical investigation. , 2008, Health technology assessment.
[18] Luke Vale,et al. Evidence-Based Decisions and Economics: Health Care, Social Welfare, Education and Criminal Justice , 2010 .
[19] M. Drummond,et al. Incorporating economics evidence , 2008 .
[20] S. Bryan,et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. , 2008, Health technology assessment.
[21] A. Dhar,et al. National Institute for Health and Clinical Excellence , 2005 .
[22] and Quality. Assessing the Impact of Economic Evidence on Policymakers In Health Care - A Systematic Review , 2013 .
[23] A. L. Cochrane,et al. Effectiveness and efficiency: random reflections on health services , 1972 .
[24] F. Pang,et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. , 2004, Health technology assessment.